Daidi Fan Spends CN¥52m On Giant Biogene Holding Stock

Giant Biogene Holding Co., Ltd. (HKG:2367) shareholders (or potential shareholders) will be happy to see that the Chief Scientific Officer, Daidi Fan, recently bought a whopping HK$52m worth of stock, at a price of HK$54.85. While that only increased their holding size by 0.2%, it is still a big swing by our standards.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

The Last 12 Months Of Insider Transactions At Giant Biogene Holding

Notably, that recent purchase by Chief Scientific Officer Daidi Fan was not the only time they traded Giant Biogene Holding shares this year. They previously made a sale of -HK$2.3b worth of shares at a price of HK$66.65 per share. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. The silver lining is that this sell-down took place above the latest price (HK$54.15). So it is hard to draw any strong conclusion from it.

Daidi Fan purchased 37.01m shares over the year. The average price per share was HK$65.89. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

View our latest analysis for Giant Biogene Holding

Giant Biogene Holding is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket.

Does Giant Biogene Holding Boast High Insider Ownership?

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Giant Biogene Holding insiders own 55% of the company, currently worth about HK$32b based on the recent share price. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.

What Might The Insider Transactions At Giant Biogene Holding Tell Us?

It's certainly positive to see the recent insider purchase. We also take confidence from the longer term picture of insider transactions. Along with the high insider ownership, this analysis suggests that insiders are quite bullish about Giant Biogene Holding. That's what I like to see! Therefore, you should definitely take a look at this FREE report showing analyst forecasts for Giant Biogene Holding.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.